Assessment of TP53 mutations in benign and malignant salivary gland neoplasms

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Gomes, Carolina Cavaliéri ^a   Diniz, Marina Gonçalves ^a   Orsine, Lissur Azevedo ^a   Duarte, Alessandra Pires ^a   Fonseca Silva, Thiago ^a   Conn, Brendan I ^b   de Marco, Luiz ^a   Pereira, Cláudia Maria ^a   Gomez, Ricardo Santiago ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53;

ADENOCARCINOMA; ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER GRADING; CARCINOGENESIS; CLINICAL ARTICLE; EXON; GENE; GENE AMPLIFICATION; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRON; MICROSATELLITE MARKER; MISSENSE MUTATION; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PLEOMORPHIC ADENOMA; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALIVARY GLAND CANCER; SALIVARY GLAND TUMOR; SINGLE NUCLEOTIDE POLYMORPHISM; TP53 GENE;

ADENOMA, PLEOMORPHIC; ADOLESCENT; ADULT; AGED; CODON, NONSENSE; EXONS; FEMALE; HUMANS; INTRONS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; MUTATION, MISSENSE; POLYMERASE CHAIN REACTION; SALIVARY GLAND NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84864070178     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041261     Document Type: Article

References (38)

1. Eveson JW, Auclair P, Gnepp DR, El-Naggar AK, (2005) Tumours of the salivary glands: introduction. In: Barnes L, Eveson JW, Reichart P, Sidransky D, editors. pp. 212-215 editors. Pathology & Genetics Head and Neck Tumours. Lyon: IARC Press.
2. de Oliveira FA, Duarte EC, Taveira CT, Maximo AA, de Aquino EC, et al. (2009) Salivary gland tumor: a review of 599 cases in a Brazilian population. Head Neck Pathol 3: 271-275.
3. Ito FA, Ito K, Vargas PA, de Almeida OP, Lopes MA, (2005) Salivary gland tumors in a Brazilian population: a retrospective study of 496 cases. Int J Oral Maxillofac Surg 34: 533-536.
4. Renehan AG, Gleave EN, Slevin NJ, McGurk M, (1999) Clinico-pathological and treatment-related factors influencing survival in parotid cancer. Br J Cancer 80: 1296-1300.
5. Adelstein DJ, Rodriguez CP, (2011) What is new in the management of salivary gland cancers? Curr Opin Oncol 23: 249-253.
6. Debaere D, Vander Poorten V, Nuyts S, Hauben E, Schoenaers J, et al. (2011) Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer. B-ENT 7: 1-6.
7. Leedham SJ, Graham TA, Oukrif D, McDonald SA, Rodriguez-Justo M, et al. (2009) Clonality, founder mutations, and field cancerization in human ulcerative colitis-associated neoplasia. Gastroenterology 136: 542-550 e546.
8. Ben-Izhak O, Laster Z, Akrish S, Muska E, Gan S, et al. (2009) The salivary tip of the p53 mutagenesis iceberg: novel insights. Cancer Biomark 5: 23-31.
9. Gomes CC, Diniz MG, Oliveira CS, Tavassoli M, Odell EW, et al. (2011) Impact of WWOX alterations on p73, DeltaNp73, p53, cell proliferation and DNA ploidy in salivary gland neoplasms. Oral Dis 17: 564-571.
10. Augello C, Gregorio V, Bazan V, Cammareri P, Agnese V, et al. (2006) TP53 and p16INK4A, but not H-KI-Ras, are involved in tumorigenesis and progression of pleomorphic adenomas. J Cell Physiol 207: 654-659.
11. Gedlicka C, Item CB, Wogerbauer M, Martinek H, Heiduschka G, et al. (2010) Transformation of pleomorphic adenoma to carcinoma ex pleomorphic adenoma of the parotid gland is independent of p53 mutations. J Surg Oncol 101: 127-130.
12. Kishi M, Nakamura M, Nishimine M, Ikuta M, Kirita T, et al. (2005) Genetic and epigenetic alteration profiles for multiple genes in salivary gland carcinomas. Oral Oncol 41: 161-169.
13. Kiyoshima T, Shima K, Kobayashi I, Matsuo K, Okamura K, et al. (2001) Expression of p53 tumor suppressor gene in adenoid cystic and mucoepidermoid carcinomas of the salivary glands. Oral Oncol 37: 315-322.
14. Weber A, Langhanki L, Schutz A, Gerstner A, Bootz F, et al. (2002) Expression profiles of p53, p63, and p73 in benign salivary gland tumors. Virchows Arch 441: 428-436.
15. El-Naggar AK, Callender D, Coombes MM, Hurr K, Luna MA, et al. (2000) Molecular genetic alterations in carcinoma ex-pleomorphic adenoma: a putative progression model? Genes Chromosomes Cancer 27: 162-168.
16. Fowler MH, Fowler J, Ducatman B, Barnes L, Hunt JL, (2006) Malignant mixed tumors of the salivary gland: a study of loss of heterozygosity in tumor suppressor genes. Mod Pathol 19: 350-355.
17. Johns MM, 3rd, Westra WH, Califano JA, Eisele D, Koch WM, et al (1996) Allelotype of salivary gland tumors. Cancer Res 56: 1151-1154.
18. Yamamoto Y, Kishimoto Y, Virmani AK, Smith A, Vuitch F, et al. (1996) Mutations associated with carcinomas arising from pleomorphic adenomas of the salivary glands. Hum Pathol 27: 782-786.
19. Kandel R, Li SQ, Ozcelik H, Rohan T, (2000) p53 protein accumulation and mutations in normal and benign breast tissue. Int J Cancer 87: 73-78.
20. Bode AM, Dong Z, (2004) Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4: 793-805.
21. Andrews GA, Xi S, Pomerantz RG, Lin CJ, Gooding WE, et al. (2004) Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head Neck 26: 870-877.
22. van Houten VM, Tabor MP, van den Brekel MW, Denkers F, Wishaupt RG, et al. (2000) Molecular assays for the diagnosis of minimal residual head-and-neck cancer: methods, reliability, pitfalls, and solutions. Clin Cancer Res 6: 3803-3816.
23. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629.
24. Liu Y, Bodmer WF, (2006) Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. Proc Natl Acad Sci U S A 103: 976-981.
25. Giefing M, Wierzbicka M, Rydzanicz M, Cegla R, Kujawski M, et al. (2008) Chromosomal gains and losses indicate oncogene and tumor suppressor gene candidates in salivary gland tumors. Neoplasma 55: 55-60.
26. Karja VJ, Syrjanen KJ, Kurvinen AK, Syrjanen SM, (1997) Expression and mutations of p53 in salivary gland tumours. J Oral Pathol Med 26: 217-223.
27. Matizonkas-Antonio LF, de Mesquita RA, de Souza SC, Nunes FD, (2005) TP53 mutations in salivary gland neoplasms. Braz Dent J 16: 162-166.
28. Castillo-Davis CI, (2005) The evolution of noncoding DNA: how much junk, how much func? Trends Genet 21: 533-536.
29. Hrstka R, Coates PJ, Vojtesek B, (2009) Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med 13: 440-453.
30. Rohan TE, Li SQ, Hartwick R, Kandel RA, (2006) p53 Alterations and protein accumulation in benign breast tissue and breast cancer risk: a cohort study. Cancer Epidemiol Biomarkers Prev 15: 1316-1323.
31. Yoshimoto T, Naruse M, Zeng Z, Nishikawa T, Kasajima T, et al. (1998) The relatively high frequency of p53 gene mutations in multiple and malignant phaeochromocytomas. J Endocrinol 159: 247-255.
32. Kontogeorgos G, Kapranos N, Thodou E, Sambaziotis D, Tsagarakis S, (1999) Immunocytochemical accumulation of p53 in corticotroph adenomas: relationship with heat shock proteins and apoptosis. Pituitary 1: 207-212.
33. Moore D, Ohene-Fianko D, Garcia B, Chakrabarti S, (1998) Apoptosis in thyroid neoplasms: relationship with p53 and bcl-2 expression. Histopathology 32: 35-42.
34. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, et al. (2004) Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23: 3328-3337.
35. Lamolle G, Marin M, Alvarez-Valin F, (2006) Silent mutations in the gene encoding the p53 protein are preferentially located in conserved amino acid positions and splicing enhancers. Mutat Res 600: 102-112.
36. Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, et al. (2011) Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A 108: 17087-17092.
37. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, et al. (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333: 1154-1157.
38. Ueno T, Yamashita Y, Soda M, Fukumura K, Ando M, et al. (2012) High-throughput resequencing of target-captured cDNA in cancer cells. Cancer Sci 103: 131-135.